NRG Oncology Combined Trial Long-Term Results Indicate that Pathologic Complete Response is Prognostic of Outcomes for Soft Tissue Sarcoma Patients
March 31 2023Combined long-term survival results from nonrandomized phase II trial NRG Oncology RTOG 0630 and the ancillary analysis of the combined NRG-RTOG 0630/9514 trials indicate that pathologic complete response (pCR) is associated with improved survival outcomes for patients with localized soft tissue sarcoma (STS) who receive preoperative chemoradiotherapy or radiotherapy. This data…
